PRESS RELEASE published on 12/13/2024 at 15:29, 1 year 7 months ago Form 8.3 - The Vanguard Group, Inc.: Britvic plc The Vanguard Group, Inc. discloses a 5.49% interest in Britvic plc's 20p ordinary securities as of 12 December 2024 Securities The Vanguard Group, Inc. Disclosure Britvic Plc Interests
BRIEF published on 12/13/2024 at 08:13, 1 year 7 months ago Transactions sur actions du directeur exécutif de Britvic Britvic Plc Simon Litherland Vente D'actions Actions Du Directeur Plan De Bonus Différé
BRIEF published on 12/13/2024 at 08:13, 1 year 7 months ago Britvic's Executive Director Share Transactions Britvic Plc Share Sale Simon Litherland Director Shares Deferred Bonus Plan
PRESS RELEASE published on 12/13/2024 at 08:08, 1 year 7 months ago Director/PDMR Shareholding Britvic plc announces vesting of deferred bonus plan shares for Executive Directors. Simon Litherland sold shares to cover tax liabilities. Details of the transaction provided Britvic Plc Executive Directors Shareholding Simon Litherland Deferred Bonus Plan
BRIEF published on 12/12/2024 at 15:46, 1 year 7 months ago Disclosure on Britvic plc by The Vanguard Group Form 8.3 Britvic Plc Takeover Code Vanguard Group Shareholding
BRIEF published on 12/12/2024 at 15:46, 1 year 7 months ago Divulgation sur Britvic plc par The Vanguard Group Britvic Plc Actionnariat Groupe Vanguard Code De Prise De Contrôle Formulaire 8.3
PRESS RELEASE published on 12/12/2024 at 15:41, 1 year 7 months ago Form 8.3 - The Vanguard Group, Inc.: Britvic plc The Vanguard Group, Inc. discloses a 5.49% ownership stake in Britvic plc as of 11 Dec 2024. Details in Form 8.3 Form 8.3 Disclosure Britvic Plc The Vanguard Group Ownership Stake
BRIEF published on 12/12/2024 at 11:11, 1 year 7 months ago UBS réduit sa participation dans Britvic PLC à moins de 5 % Droit De Vote Émetteur Britannique Britvic Réduction Des Stocks UBS
BRIEF published on 12/12/2024 at 11:11, 1 year 7 months ago UBS Reduces Stake in Britvic PLC Below 5% Voting Rights UK Issuer Britvic UBS Stock Reduction
PRESS RELEASE published on 12/12/2024 at 11:06, 1 year 7 months ago Holding(s) in Company UBS Group AG's trading book holdings in BRITVIC PLC fell below 5% threshold, exempting them from reporting. Notification made on 12-Dec-2024 Britvic Plc Notification Threshold UBS Group AG Trading Book Holdings
Published on 08/10/2026 at 08:00, 2 hours 48 minutes ago Galantas Gold Expands Indiana Drill Program to 12,500 Metres
Published on 08/10/2026 at 08:00, 2 hours 48 minutes ago Results of AGM and Management Update Presentation
Published on 08/07/2026 at 23:15, 2 days 11 hours ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 2 days 11 hours ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/10/2026 at 10:12, 36 minutes ago Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 08/10/2026 at 10:10, 38 minutes ago Hana Bank Subsidiary GLN Expands QR Payment Network for International Travelers to Korea
Published on 08/10/2026 at 09:50, 58 minutes ago Photon Energy N.V. Bond 21/27 (ISIN: DE000A3KWKY4): Signs of a crisis are mounting. What can investors do? Invitation to video conferences (German/English)
Published on 08/10/2026 at 09:00, 1 hour 48 minutes ago Original-Research: Rosenbauer International AG (von NuWays AG): BUY
Published on 08/10/2026 at 09:00, 1 hour 48 minutes ago Original-Research: Bittium Oyj (von NuWays AG): BUY
Published on 08/10/2026 at 09:47, 1 hour 1 minute ago 260810 BENETEAU Transactions sur actions propres
Published on 08/10/2026 at 09:22, 1 hour 26 minutes ago Number of shares and voting rights - July 2026 (In French only)
Published on 08/10/2026 at 09:22, 1 hour 26 minutes ago Nombre total d'actions et droits de vote - juillet 2026
Published on 08/10/2026 at 07:00, 3 hours 48 minutes ago BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Published on 08/10/2026 at 07:00, 3 hours 48 minutes ago Biophytis annonce l’autorisation de l’étude clinique OBA au Brésil et partage les perspectives de BIO101 dans l’obésité
